| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (November 5, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (August 6, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026. |
| 18 May 2026 |
8-K: Regulation FD Disclosure; Other Events
This SECURITIES PURCHASE OPTION AGREEMENT (the “Agreement”) is made and entered into as of September 11, 2019 (the “Effective Time”) by and among CryoLife, Inc., a Florida corporation (“Buyer”), Endospan Ltd., an Israeli corporation (the... |
| 15 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At Artivion, Inc.’s (the “Company” or “Artivion”) 2026 Annual Meeting of Stockholders held on May 12, 2026 (the “Annual Meeting”), Artivion’s stockholders elected each individual that was nominated for election as director of the Company... |
| 07 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
This SECURITIES PURCHASE OPTION AGREEMENT (the “Agreement”) is made and entered into as of September 11, 2019 (the “Effective Time”) by and among CryoLife, Inc., a Florida corporation (“Buyer”), Endospan Ltd., an Israeli corporation (the... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
1 Adjusted revenue excludes a $2.3 million reserve for estimated payback to the Italian government for fiscal years 2019 through 2025 as a result of legislation adopted in Italy that would require medical device manufacturers to repay pr... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (November 6, 2025) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025. |
| 29 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED |
| 15 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT, dated as of September 12, 2025 (this “Amendment Agreement”), by and among ARTIVION, INC., a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party hereto from time ... |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 6, 2025, the Board of Directors of Artivion, Inc. (the “Company”) appointed Lance A. Berry, the Company’s current Executive Vice President, Chief Financial Officer and Treasurer, as the Company’s Chief Operating Officer, effect... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (August 7, 2025) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2025. |
| 29 May 2025 |
8-K: Unregistered Sales of Equity Securities; Other Events
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock |
| 16 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
1.1 Purpose. The Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) has been established by Artivion, Inc. (the “Company”)1 to (i) attract, retain, and reward persons eligible to participate in the Plan;... |
| 14 May 2025 |
8-K: Unregistered Sales of Equity Securities; Other Events
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (May 5, 2025) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2025. |
| 24 Feb 2025 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (February 24, 2025) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and year ended December 31, 2024. |
| 23 Dec 2024 |
8-K: Other Events
On December 23, 2024, in accordance with the Indenture (the “Indenture”) dated June 23, 2020, between Artivion, Inc. (formerly CryoLife, Inc.) (the “Company”) and U.S. Bank Trust Company, National Association, as Trustee, relating to the... |
| 09 Dec 2024 |
8-K: Other Events
ATLANTA, GA – (December 9, 2024) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device ... |
| 09 Dec 2024 |
8-K: Other Events
Artivion, Inc. (“Artivion” or the “Company”) identified and began taking measures to address a cybersecurity incident on November 21, 2024. Artivion’s response measures included taking certain systems offline, initiating an investigation... |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (November 7, 2024) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2024. |
Loading...